Your browser doesn't support javascript.
loading
Cord blood transplantation for adult mature lymphoid neoplasms in Europe and Japan.
Watanabe, Mizuki; Kanda, Junya; Volt, Fernanda; Ruggeri, Annalisa; Suzuki, Ritsuro; Rafii, Hanadi; Kimura, Fumihiko; Cappelli, Barbara; Kondo, Eisei; Scigliuolo, Graziana Maria; Takahashi, Satoshi; Kenzey, Chantal; Rivera-Franco, Monica M; Okamoto, Shinichiro; Rocha, Vanderson; Chevallier, Patrice; Sanz, Jaime; Fürst, Sabine; Cornelissen, Jan; Milpied, Noel; Uchida, Naoyuki; Sugio, Yasuhiro; Kimura, Takafumi; Ichinohe, Tatsuo; Fukuda, Takahiro; Mohty, Mohamad; Peffault de Latour, Régis; Atsuta, Yoshiko; Gluckman, Eliane.
Afiliación
  • Watanabe M; Department of Hematology, Kyoto University Hospital, Kyoto, Japan.
  • Kanda J; Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
  • Volt F; Department of Hematology, Kyoto University Hospital, Kyoto, Japan.
  • Ruggeri A; Eurocord, Hopital Saint Louis, Assistance Publique - Hopitaux de Paris, Institut de Recherche de Saint-Louis EA3518, Université de Paris Cité, Paris, France.
  • Suzuki R; Eurocord, Hopital Saint Louis, Assistance Publique - Hopitaux de Paris, Institut de Recherche de Saint-Louis EA3518, Université de Paris Cité, Paris, France.
  • Rafii H; Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Kimura F; Department of Oncology/Hematology, Shimane University School of Medicine, Izumo, Japan.
  • Cappelli B; Eurocord, Hopital Saint Louis, Assistance Publique - Hopitaux de Paris, Institut de Recherche de Saint-Louis EA3518, Université de Paris Cité, Paris, France.
  • Kondo E; Division of Hematology, National Defense Medical College, Tokorozawa, Japan.
  • Scigliuolo GM; Eurocord, Hopital Saint Louis, Assistance Publique - Hopitaux de Paris, Institut de Recherche de Saint-Louis EA3518, Université de Paris Cité, Paris, France.
  • Takahashi S; Monacord, Centre Scientifique de Monaco, Monaco.
  • Kenzey C; Department of Hematology, Kawasaki Medical School, Okayama, Japan.
  • Rivera-Franco MM; Eurocord, Hopital Saint Louis, Assistance Publique - Hopitaux de Paris, Institut de Recherche de Saint-Louis EA3518, Université de Paris Cité, Paris, France.
  • Okamoto S; Monacord, Centre Scientifique de Monaco, Monaco.
  • Rocha V; Division of Molecular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Chevallier P; Eurocord, Hopital Saint Louis, Assistance Publique - Hopitaux de Paris, Institut de Recherche de Saint-Louis EA3518, Université de Paris Cité, Paris, France.
  • Sanz J; Eurocord, Hopital Saint Louis, Assistance Publique - Hopitaux de Paris, Institut de Recherche de Saint-Louis EA3518, Université de Paris Cité, Paris, France.
  • Fürst S; Division of Hematology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Cornelissen J; Eurocord, Hopital Saint Louis, Assistance Publique - Hopitaux de Paris, Institut de Recherche de Saint-Louis EA3518, Université de Paris Cité, Paris, France.
  • Milpied N; Service of Hematology, Transfusion and Cell Therapy, and Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Hospital das Clínicas, Faculty of Medicine, São Paulo University, São Paulo, Brazil.
  • Uchida N; Department D'Hematologie, Centre Hospitalier Universitaire de Nantes, Nantes, France.
  • Sugio Y; Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
  • Kimura T; Department of Hematology, Institut Paoli Calmettes, Marseille, France.
  • Ichinohe T; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Fukuda T; Service d'Hématologie Clinique et Thérapie Cellulaire, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
  • Mohty M; Department of Hematology, Federation of National Public Service Personnel Mutual Aid Associations, Tokyo, Japan.
  • Peffault de Latour R; Department of Hematology, Kitakyusyu City Hospital Organization, Kitakyusyu Municipal Medical Center, Fukuoka, Japan.
  • Atsuta Y; Preparation Department, Japanese Red Cross Kinki Block Blood Center, Ibaraki, Japan.
  • Gluckman E; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima, Japan.
Blood Adv ; 8(3): 640-652, 2024 02 13.
Article en En | MEDLINE | ID: mdl-38100431
ABSTRACT
ABSTRACT To clarify the different characteristics and prognostic factors of cord blood transplantation (CBT) in adult patients with lymphoid neoplasms in Europe and Japan, we conducted a collaborative study. Patients aged 18-75 years receiving their first CBT (Europe single CBT, n = 192; double CBT, n = 304; Japan single CBT, n = 1150) in 2000-2017 were analyzed. Fewer patients with Hodgkin lymphoma (Europe vs Japan, 26% vs 5%), and older patients (≥50 years) (39% vs 59%) with a higher refined disease risk index (rDRI) (high-very high 49% vs 14%) were included in the Japanese registry. High-very high rDRI was associated with inferior overall survival (OS) (vs low rDRI, Europe hazard ratio [HR], 1.87; P = .001; Japan HR, 2.34; P < .001) with higher progression/relapse risks. Total body irradiation (TBI)-containing conditioning contributed to superior OS both in Europe (vs TBI-reduced-intensity conditioning [RIC], non-TBI-RIC HR, 1.93; P < .001; non-TBI-Myeloablative conditioning [MAC] HR, 1.90; P = .003) and Japan (non-TBI-RIC HR, 1.71; P < .001; non-TBI-MAC HR 1.50, P = .007). The impact of HLA mismatches (≥2) on OS differed (Europe HR, 1.52; P = .007; Japan HR, 1.18; P = .107). CBT for lymphoid neoplasms, especially in those with high rDRI showed poor outcomes despite all the different characteristics in both registries. TBI should be considered in conditioning regimens to improve these outcomes. The different impacts of HLA mismatches call attention to the fundamental differences among these populations.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Asunto principal: Trasplante de Células Madre Hematopoyéticas / Trasplante de Células Madre de Sangre del Cordón Umbilical / Enfermedad Injerto contra Huésped / Linfoma Límite: Adult / Humans País/Región como asunto: Asia Idioma: En Revista: Blood Adv Año: 2024 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Asunto principal: Trasplante de Células Madre Hematopoyéticas / Trasplante de Células Madre de Sangre del Cordón Umbilical / Enfermedad Injerto contra Huésped / Linfoma Límite: Adult / Humans País/Región como asunto: Asia Idioma: En Revista: Blood Adv Año: 2024 Tipo del documento: Article País de afiliación: Japón